The Alzheimer’s Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California, San Diego. The ADCS is a major initiative for Alzheimer’s disease (AD) clinical studies in the Federal Government, addressing treatments for both cognitive and behavioral symptoms. The ADCS is part of the NIA Division of Neuroscience’s effort to facilitate the discovery, development and testing of new drugs for the treatment of AD and is part of the Alzheimer’s Disease Prevention Initiative as well.
EXERT is a national, 18-month clinical trial to test whether physical exercise can slow the progression of early Alzheimer’s disease-related memory problems or mild cognitive impairment in older adults.
The Discover Study is a randomized, double-blind, placebo controlled study. Participants will be treated with a low, middle, or high dose of Posiphen, or a placebo.
PEACE AD is a multi-center, randomized, placebo-controlled study evaluating the efficacy and safety of the 旋风加速器APP
T2 is designed to determine if troriluzole can protect, slow down, or potentially improve memory and thinking problems that increase as Alzheimer’s disease progresses.
The NEAT study is a clinical trial sponsored by the University of California Cures for Alzheimer’s Initiative grant, focusing on nicotinamide, a dissolving form of vitamin B3.
Led by Mt Sinai Alzheimer’s researcher and thought leader Mary Sano, PhD, and coordinated by the ADCS, the HBA study compared feasibility and efficiency, and ability to capture change over time using in-home instruments, and ability to predict cognitive conversion using pre-defined triggers in a randomized clinical trial.
Watch a Brain Channel round table about educating, training, mentoring and funding young Latino Alzheimer’s scientists.
What’s next in the Raskind/Peskind Prazosin research? They are directing the ADCS’ Peace AD trial which will test Prazosin, as a treatment for disruptive agitation, in people with moderate to severe Alzheimer’s disease. The trial is launching this spring in over 20 memory and long term care communities in the US.
The AlzForum’s editorial team provides a comprehensive recap of the last year in Alzheimer’s research and related public policy developments.
The updated guidelines reflect increased MCI research, the significance of MCI in clinical practice, and therapeutics in trials.
Link to the report home page, summary, and PDFs of the full report.
From the accompanying JAMA Neurology editorial “What is clear is that, with the advance of molecular diagnostic tools in neurology, clinicians and investigators will increasingly be faced with the challenge of presenting patients with information of uncertain prognostic significance. The investigators of the A4 study are to be commended for developing a thoughtful process of…
